The Latest Cardiac and Vascular News
CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL, an Asahi Kasei company, has been selected to exhibit SuperSaturated Oxygen (SSO2) Therapy, which delivers high levels of dissolved oxygen directly to the heart following severe heart attack, at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s […]
Study Evaluates the Effectiveness of TherOx Supersaturated Oxygen (SSO2) Therapy in Patients Presenting with Acute Anterior Myocardial Infarction with Successful Reperfusion Compared to Standard Therapy CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software […]
CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the American Medical Association (AMA) CPT Editorial Panel issued a new Category III CPT® code, effective July 1, 2021, for its TherOx® SuperSaturated […]
Study Evaluates the Safety and Feasibility of TherOx Supersaturated Oxygen (SSO2) Therapy in STEMI Patients presenting with Cardiogenic Shock CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today the U.S. […]
May 4, 2020 — CHELMSFORD, MASS. — ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today it has received CE Mark approval to market and distribute its SuperSaturated Oxygen (SSO2) Therapy System in Europe. SSO2 Therapy […]
First and Only Treatment to Reduce Heart Muscle Damage Following Angioplasty and Stenting CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL® Medical Corporation, an Asahi Kasei Group company that manufactures medical devices and related software solutions, announced today it has received U.S. Food and Drug Administration […]
CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, today announced it has acquired TherOx, Inc., of Irvine, Calif., a privately held company. TherOx is focused on improving treatment of acute myocardial […]
IRVINE, Calif.–(BUSINESS WIRE)–TherOx, Inc., a privately held medical device company focused on improving treatment of acute myocardial infarction (AMI), announced that the U.S. Food and Drug Administration (FDA) granted premarket approval for its SuperSaturated Oxygen (SSO2) Therapy. SSO2 Therapy provides interventional […]
Supports U.S. Market Introduction of SuperSaturated Oxygen Therapy for Improved AMI Patient Outcomes Irvine, Calif., May 7, 2018 – TherOx®, a privately held medical device company focused on improving treatment of acute myocardial infarction (AMI), today announced completion of a […]
IRVINE, Calif.–(BUSINESS WIRE)–TherOx, Inc., a privately held medical device company focused on improving treatment of Acute Myocardial Infarction (AMI), announced that the U.S. Food and Drug Administration (FDA) has accepted the Premarket Approval (PMA) application for its Supersaturated Oxygen (SSO2) […]
